| May 7 |
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024
|
| May 6 |
NRx Pharmaceuticals climbs on positive results from its bipolar depression treatment trial
|
| May 6 |
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression
|
| Apr 30 |
Why Is NRx Pharmaceuticals Stock Falling After Data From Suicidal Bipolar Depression Study
|
| Apr 30 |
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression
|
| Apr 18 |
NRx Pharmaceuticals receives Nasdaq notice on demonstrating compliance with bid price requirement
|
| Apr 18 |
NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement
|
| Apr 18 |
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
|
| Apr 17 |
NRx Pharmaceuticals announces proposed underwritten public offering of common stock
|
| Apr 17 |
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections
|
